Calbindin-1 association and Parkinson's disease

European Journal of Neurology

Volumn 17, Issue 2, 2010, Pages 208-211

  Soto Ortolaza, A I ^a   Behrouz, B ^a   Wider, C ^a   Vilarino Guell C ^a   Heckman, M G ^b   Aasly, J O ^c,d   Mark Gibson, J ^e   Lynch, T ^f,g   Jasinska Myga, B ^a,h   Krygowska Wajs, A ⁱ   Opala, G ^h   Barcikowska, M ^j   Czyzewski, K ^k   Uitti, R J ^b   Wszolek, Z K ^b   Farrer, M J ^a   Ross, O A ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^e ROYAL VICTORIA HOSPITAL   (United Kingdom)

^f MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^g UNIVERSITY COLLEGE DUBLIN   (Ireland)

^h MEDICAL UNIVERSITY OF SILESIA   (Poland)

ⁱ JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^j MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^k CENTRAL CLINICAL HOSPITAL OF THE MINISTRY OF INTERIOR   (Poland)

more..

Author keywords

Association study; Calbindin 1; Genetics; Parkinson's disease

Indexed keywords

CALBINDIN;

ADULT; AGED; ARTICLE; CAUCASIAN; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IRELAND; MALE; MIDDLE AGED; NORWAY; PARKINSON DISEASE; POLAND; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SEQUENCE ANALYSIS, DNA; UNITED STATES;

EID: 74549147308     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2009.02769.x     Document Type: Article

References (21)

1. de Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community concerted action on the epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997 62 : 10 15.
2. de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 2004 63 : 1240 1244.
3. Riederer P, Wuketich S. Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 1976 38 : 277 301.
4. Chan CS, Gertler TS, Surmeier DJ. Calcium homeostasis, selective vulnerability and Parkinson's disease. Trends Neurosci 2009 32 : 249 256.
5. Mattson MP. Calcium and neurodegeneration. Aging Cell 2007 6 : 337 350.
6. 2+ channels. Neuroreport 2006 17 : 1883 1886.
7. Danzer KM, Haasen D, Karow AR, et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 2007 27 : 9220 9232.
8. Tamamizu-Kato S, Kosaraju MG, Kato H, Raussens V, Ruysschaert JM, Narayanaswami V. Calcium-triggered membrane interaction of the alpha-synuclein acidic tail. Biochemistry 2006 45 : 10947 10956.
9. Mosharov EV, Larsen KE, Kanter E, et al. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 2009 62 : 218 229.
10. Fitzpatrick E, Ashkan K, Wallace BA, Benabid AL, Mitrofanis J. Differential survival patterns among midbrain dopaminergic cells of MPTP-treated monkeys and 6OHDA-lesioned rats. Anat Embryol (Berl) 2005 210 : 101 123.
11. German DC, Manaye KF, Sonsalla PK, Brooks BA. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann N Y Acad Sci 1992 648 : 42 62.
12. Lavoie B, Parent A. Dopaminergic neurons expressing calbindin in normal and parkinsonian monkeys. Neuroreport 1991 2 : 601 604.
13. McCormack AL, Atienza JG, Langston JW, Di Monte DA. Decreased susceptibility to oxidative stress underlies the resistance of specific dopaminergic cell populations to paraquat-induced degeneration. Neuroscience 2006 141 : 929 937.
14. Mizuta I, Tsunoda T, Satake W, et al. Calbindin 1, fibroblast growth factor 20, and alpha-synuclein in sporadic Parkinson's disease. Hum Genet 2008 124 : 89 94.
15. Surmeier DJ. A lethal convergence of dopamine and calcium. Neuron 2009 62 : 163 164.
16. Mizuta I, Satake W, Nakabayashi Y, et al. Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum Mol Genet 2006 15 : 1151 1158.
17. Maraganore DM, de Andrade M, Elbaz A, et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006 296 : 661 670.
18. Maraganore DM, de Andrade M, Lesnick TG, et al. High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet 2005 77 : 685 693.
19. Di Fonzo A, Wu-Chou YH, Lu CS, et al. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 2006 7 : 133 138.
20. Ross OA, Wu YR, Lee MC, et al. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neurol 2008 64 : 88 92.
21. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005 21 : 263 265.